Does Giant Cell Glioblastoma Have a Better Prognosis in Comparison to Glioblastoma Multiform? A Secondary Analysis of the SEER Database from 1985-2014

Amro K. Bin Abdulrahman MD1*, Yousef R. Bukhari MD1, Abdulaziz M. Faqihi MD1, Khalid A. Bin Abdulrahman Prof. Dr. 1, Juan Gabriel Ruiz Associate Prof.2.

draka.1416@gmail.com, yousef.bukhary@gmail.com, azoz.mf@hotmail.com, kab@imamu.edu.sa, jruizpel@fiu.edu

1College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia
2Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

Correspondence:
Amro Khalid Bin Abdulrahman
College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU)
P.O. Box: 7544 – Othman Bin Affan Rd. Al-Nada
Riyadh 13317 – 4233 - Saudi Arabia
Mobile: +966 555902563
Email: akabdulrahman@sm.imamu.edu.sa

Abstract:
Brain cancer is the tenth leading cause of death in the U.S. Glioblastoma multiforme (GBM) is the most lethal primary malignant central nervous system tumor in adults. The present study employed samples from 1985-2014 to discover the difference in prognosis among glioblastoma subtypes after the evolution of treatment modalities over the past few years. The current study aims to find the differences between Glioblastoma multiforme (GBM) and giant cell glioblastoma (GCG) in terms of prognosis among adults and elderly patients in the U.S.
This study is a historical cohort type of study and is conducted on adults and elderly individuals with GBM or GCG from the years 1985-2014 in the U.S. Data were collected from the Surveillance, Epidemiology, and End Results Program (SEER) database. The study exposure was GBM or GCG and the outcome was mortality. The potential confounders were age, sex, race, ethnicity, year of diagnosis, primary site, and surgery. A chi-square test was used for categorical data. A univariate analysis was used for variables having a p-value < 0.05. Potential confounders were selected and evaluated using multivariate logistic regression models to calculate the odds ratio with stepwise selection.

The study sample was 25,117. The incidences of GBM and GCG were not similar in relation to age group. Also, Spanish-Hispanic ethnicity was independently protective of GBM and GCG as compared to Non-Spanish-Hispanic ethnicity patients with GBM have a higher mortality rate than do GCG patients. The mortality rate was higher among patients diagnosed before 2010. In conclusion, GCG was not statistically significant in association to reduced mortality. Non-Spanish-Hispanics with GBM or GCG had a higher mortality rate than did Spanish-Hispanics. Factors such as being female, being age >59, and having a year of diagnosis before 2010 were independently associated with increased mortality.

Key words: Brain Cancer, Glioblastoma multiforme, Giant Cell Glioblastoma, Prognosis

1. Introduction

Brain cancer and other nervous system cancers are the tenth leading cause of death in the U.S. Brain cancer is common among adults and elderly individuals [1].

Glioblastoma multiforme (GBM) is a common malignant tumor that originates from astrocytes. It is a rapid-growing tumor that affects the nervous system, including the brain and the spinal cord [2].

It is estimated that GBM cases in the U.S. account for approximately 20% of all primary CNS tumors in the adult population and almost 75% of all anaplastic gliomas [3]. Glioblastoma multiforme (GBM) is the most lethal primary malignant central nervous system tumor in adults [4-6]. GBM incidence and prognosis have changed over the past few years. This has been explained by several risk factors, such as sex, age group, race, ethnicity, year of
diagnosis, primary site, and surgical removal of the tumor [7-8]. It has been found that the overall prognosis of patients with GBM is poor, with a median survival of 14.6 months and a five-year survival rate of <5% [4,9]. A review of the relevant literature, which included a well-conducted systematic review [10], provided evidence of an association between survival in cases of glioblastoma and several prognostic factors, including age at diagnosis, sex, race/ethnicity, primary site, and treatment (including surgery). However, no information was available about the effect of subtypes of glioblastoma and prognosis, particularly in terms of whether survival in cases of giant cell glioblastoma was different from that in cases of other subtypes of glioblastoma multiforme. Kozak and Moody conducted a study using the Surveillance, Epidemiology, and End Results (SEER) database from 1988-2004, with which they made a comparison between GCG and GBM and found that GCG had a better prognosis [11]. The present study included samples from 1985-2014 to discover the difference in prognosis between glioblastoma subtypes after the evolution of treatment modalities over the past few years. Therefore, the current study aimed to find the differences between GBM and GCG regarding prognosis among adults and elderly patients in the U.S.

2. Materials and Methods

2.1 Study strategy and data source:

A historical cohort was assembled using data from the Surveillance, Epidemiology, and End Results (SEER) database in July 2017 (http://www.seer.cancer.gov/). The data was collected via SEER*Stat software from 1985-2014. The SEER program was established in 1973 by the U.S. NCI and collects incidences and survival records of patients with malignant tumors from 18 population-based cancer registries in the U.S. [12]. The registries represent
approximately 28% of the population of the U.S.; registries were selected, in part, for their diverse population subgroups. These surveys have multi-stage sampling and are considered to be complex, overestimated, and not representative of the entire U.S. population. However, SEER does its own modeling through extrapolation.

2.2 Study population:

Patients aged younger than 20 years have a lower incidence rate; frequency rapidly increases starting in the fifth decade of life [13]. Therefore, the inclusion criteria for the analysis were patients with a confirmed diagnosis of GBM or GCG at age 18 or older from the years 1985-2014. The exclusion criteria included insurance, grading, and tumor size, due to a high percentage (over 25%) of missing data in the SEER database. The SEER database included patients’ insurance data from the years 2007 and onwards. Also, in terms of tumor size, 65% of data was missing in the database. However, glioblastoma has no clear grading system, as it is a type of glioma and is considered the most malignant type (type 4). Therefore, grading was also excluded [14].

2.3. Ethical Considerations

Ethical approval was waived, since the analysis was considered nonhuman subjects research by the Florida International University Health Science Institutional Review Board.

2.4 Study variables:

The study variables included data of GBM patients (histology codes: ICD-O-3:9440/3, 9441/3) with tumors located in several locations: supratentorial (cerebrum, frontal lobe, temporal lobe, parietal lobe, occipital lobe), brain overlap, and infratentorial (cerebellum,
ventricle, and brainstem). In addition, primary site codes (C71.0-C72.0) were extracted from the SEER database. Diagram 1 shows the variables that were analyzed.

In addition, the SEER research data record description was used to categorize other variables such as race, which was categorized into White, Black, and Others. Ethnicity was also categorized into Non-Spanish Hispanic-Latino and Spanish-Hispanic-Latino. Year of diagnosis was categorized into years before 2010 and years 2010-2014 due to the approval of Bevacizumab for recurrent glioblastoma in 2010 [15].

2.5 Statistical analysis:

First, the population was selected from the SEER database. Then, the characteristics of the population were described. After that, the general distribution of the data was examined. Next, some variables were transformed into appropriate categories (e.g. age group was categorized into adults from 18-59 years old and elderly individuals >59 years old) [16]. The primary site was categorized into supratentorial, brain overlap (including the brain ventricles and other unspecified brain locations), and infratentorial regions. The alpha level was set at 0.2 due to the small sample size of GCG incidences in the SEER database.

A chi-square test was used for categorical data. Categorical data were expressed by numbers (n) and percentage (%). A univariate analysis was used for variables having a p-value < 0.05, while potential confounders (patient’s sex, age group, race, ethnicity, year of diagnosis, primary site, and surgery) were selected and evaluated by multivariate logistic regression models to calculate the odds ratio with stepwise selection. A collinearity model was used to
determine the relationship between each of the confounders for the exclusion of dependent variables. However, no significant relationship between the confounders was excluded.

2.6 Data Availability

The Surveillance, Epidemiology, and End Results (SEER) data used to support the findings of this study were supplied by the National Cancer Institute under license and so cannot be made freely available. Requests for access to these data should be made to the National Cancer Institute (http://www.seer.cancer.gov/).

Diagram 1: Variables were analyzed using the SEER database and Stata software
3. Results

The study sample was 25,117. It included 24,909 patients with GBM and 208 with GCG. However, 88.3% of patients with GBM died within a few years, while 84.1% of GCG patients also died from the tumor. The baseline characteristics of the study sample are explained in table 1, which shows that gender has a slight variation in GBM and GCG incidences. Males are more likely to develop GBM than GCG; conversely, females are more likely to develop GCG. Table 1 also shows that the incidence of GBM and GCG is not similar in relation to age group. Hence, it is statistically significant that adults have a higher predisposition to developing GCG than GBM.
Race also reveals some variations in terms of the two subtypes of glioblastoma, with individuals who have a white racial background being more prone to GBM, while individuals of other races being more prone to GCG. The Non-Spanish-Hispanic-Latino ethnicity has a slightly higher incidence of GBM than GCG, while, inversely, Spanish-Hispanic-Latinos

| Type of Glioblastoma | Characteristics | **GBM** (NOS) | **GCG** | P-value |
|----------------------|----------------|---------------|--------|---------|
| Sex                  | Male           | 14,375 (57.7) | 115 (55.3) | 0.481 |
|                      | Female         | 10,534 (42.3) | 93 (44.7) |        |
| Age group            | Adults (18-59) | 10,221 (41.0) | 120 (57.7) | <0.001 |
|                      | Elderly (>60)  | 14,686 (59.0) | 88 (42.3) |        |
| Race                 | White          | 22,700 (91.3) | 184 (88.5) | 0.318 |
|                      | Black          | 1,169 (4.7)   | 12 (5.8)  |        |
|                      | Other          | 994 (4.0)     | 12 (5.8)  |        |
| Ethnicity            | Non-Spanish-Hispanic-Latino | 23,791 (95.5) | 192 (92.3) | 0.027 |
|                      | Spanish-Hispanic-Latino | 1,118 (4.5) | 16 (8) |        |
| Year of diagnosis    | Before 2010    | 20,719 (83.3) | 171 (82.2) | 0.71 |
|                      | 2010-2014      | 4,190 (16.8) | 37 (17.8) |        |
| Primary Site         | Supratentorial | 17,828 (71.6) | 168 (80.8) | <0.001 |
|                      | Brain overlap  | 6,767 (27.2)  | 33 (15.9) |        |
|                      | Infratentorial | 314 (1.3)     | 7 (3.4)   |        |
| Surgery              | None           | 3,287 (26.1)  | 13 (11.4) | <0.001 |
|                      | No GTR         | 5,719 (45.5)  | 50 (43.9) |        |
|                      | GTR            | 3,574 (28.4)  | 51 (44.7) |        |

1 GBM = Glioblastoma Multiforme.
2 NOS = Not Otherwise Specified, 2GBM = Glioblastoma Multiforme, 3GCG= Giant Cell Glioblastoma.

154 Race also reveals some variations in terms of the two subtypes of glioblastoma, with individuals who have a white racial background being more prone to GBM, while individuals of other races being more prone to GCG. The Non-Spanish-Hispanic-Latino ethnicity has a slightly higher incidence of GBM than GCG, while, inversely, Spanish-Hispanic-Latinos...
have fewer incidences of GBM than GCG. The incidence of GBM was slightly higher than the incidence of GCG before 2010; after 2010, the incidence of GCG was higher. However, incidences of both tumors have decreased considerably since 2010.

The study reveals some statistically significant differences in terms of tumor primary site, with high statistical significance. Both subtypes of tumors originate more often in the supratentorial part of the brain than elsewhere in the central nervous system. However, GCG tumors originate more from the supratentorial site than do GBM tumors. It is also statistically significant that GBM risk is higher in patients with no surgery or no gross total resection, while patients with gross total resection (GTR) have an elevated GCG risk. Table 2 shows that patients with GBM have a higher mortality rate than do GCG patients. Table 3 shows that GCG has an odds ratio [OR] of 0.56 with a confidence interval of 0.53-1.44, which is independently associated with reduced mortality.

Table 2 also shows a slight difference in mortality between age groups in relation to the two glioblastoma subtypes; this difference is statistically significant. It indicates that elderly patients have a worse prognosis than do adults. Glioblastoma patients with a white racial background also face a slightly increased risk of death. The Spanish-Hispanic-Latino ethnicity has a lower mortality rate than do Non-Spanish-Hispanic-Latinos, as explained in table 3. The Spanish-Hispanic-Latino ethnicity is independently protective from GBM and GCG (OR 0.63, CI =0.52-0.77). GBM and GCG tumors with brain overlap have a statistically significant worse outcome than do other primary tumor sites, as shown in table 2.
Surgery also plays a role in patients’ outcomes. The mortality rate increases in patients with no tumor resection. As shown in table 3, the factors independently associated with increased mortality are: being female ([OR] 1.12, CI =1.01-1.25), being age >59 years (OR 1.64, CI =1.48-1.82), and being diagnosed earlier than 2010 (OR 5.26, CI =4.74 - 5.84). Table 4 shows some of the incidental findings.
Table 3: Odds ratio of GBM and GCG patients from 1985-2014 in the U.S.

| Characteristics | Unadjusted | ^1Adjusted |
|-----------------|------------|------------|
|                 | ^2 OR (95% CI) | N | OR (95% CI) | N |
| Glioblastoma    |            |   |            |   |
| GBM             | Reference  |   |            |   |
| GCG             | 0.70 (0.5-1.02) | 25,117 | 0.88 (0.53-1.44) | 12,694 |

^1 Adjusted for age, sex, race, ethnicity, year of diagnosis, and primary site surgery.
^2 OR = Odds Ratio.
^3 CI = Confidence Interval.
^4 GBM = Glioblastoma Multiforme.
^5 GCG = Giant Cell Glioblastoma.

Table 4: Incidental findings of race/ethnicity and the year of diagnosis.

| Characteristics | Unadjusted | Adjusted |
|-----------------|------------|----------|
|                 | ^1 OR (95% CI) | ^2 P-value | OR (95% CI) | P-value |
| Race            |            |          |            |          |
| White           | REF        |          |            |          |
| Black           | 0.61 (0.52-0.71) | <0.001 | 0.64 (0.52-0.79) | <0.001 |
| Others          | 0.50 (0.43-0.60) | <0.001 | 0.61 (0.50-0.75) | <0.001 |
| Ethnicity       |            |          |            |          |
| Non-Spanish-Hispanic | REF | |            |          |
| Spanish-Hispanic-Latino | 0.57 (0.49-0.67) | <0.001 | 0.63 (0.52-0.77) | <0.001 |
| Year of Diagnosis |            |          |            |          |
| Before 2010     | 5.44 (5.01-5.91) | <0.001 | 5.26 (4.74 - 5.84) | <0.001 |
| 2010-2014       | REF        |          |            |          |

^1 OR = Odds Ratio.
^2 CI = Confidence Interval.
4. Discussion

To the best of our knowledge, this study is one of the few that address the association of subtype of glioblastoma and mortality in adults in the U.S. after 2010 and that involve a large sample size in GCG and GBM with the utilization of ICD-0-3 codes. GBM is more common than GCG and has a higher mortality rate. On the other hand, the current study provides statistically significant data about ethnicity, explaining that the Spanish-Hispanic-Latino ethnicity is independently protective from both glioblastoma subtypes as compared to the Non-Spanish-Hispanic ethnicity. Furthermore, factors like being female, being age >59, and having a year of diagnosis before 2010 are independently associated with increased mortality.

This study found that elderly individuals have the highest mortality rate among GBM and GCG patients in comparison to adults (p<0.001). Some studies were consistent with the previous findings [17-20]. Therefore, age is considered a significant predictor of survival time [21]. This study also demonstrates that elderly individuals are more prone to having GBM than GCG, which explains the rarity of GCG. This finding may indicate that the elderly population is more susceptible to GBM due to an increased chance that cells will mutate into cancer cells. The current study demonstrated that more males are afflicted with GBM than with GCG, while more females are afflicted with GCG (P=0.481), consistent with [3,22-26].

Another study, conducted on Black patients with GBM, showed that Black males were affected by GBM more than were Black females [27]. Therefore, GCG, an uncommon type of glioblastoma multiform, more often affects females. However, GBM affects males more than females, regardless of race. The previous findings may be explained by genetic factors.
The present study stated that the mortality rate is higher among GBM and GCG patients diagnosed before 2010 (P<0.001). Also, one study showed that the prognosis for elderly patients with glioblastoma has improved since the introduction of the Stupp regimen (i.e., radiotherapy plus concomitant and adjuvant temozolomide) in 2005 [21]. This indicates that year of diagnosis has a significant impact on the prognosis of glioblastoma patients. However, the proportion of patients with GBM is slightly higher than the proportion of GCG patients before 2010. On the other hand, the proportion of GCG incidences is slightly higher than the proportion of GBM incidences after 2010 (P=0.71).

Patients who didn’t have a Gross Total Resection (GTR) have a higher mortality rate (P<0.001). Moreover, patients who hadn’t undergone surgery or GTR developed GBM more often than they did GCG (P<0.001).

Studies like [28,29] had similar findings, stating that GTR has a better survival rate than does partial resection or biopsy. Brain overlap GBM and GCG tumors are associated with higher mortality rates than are supratentorial and infratentorial tumors (P<0.001). This finding was similar in one study [3].

However, another study showed that the median survival time for both cerebellar GBM (cGBM) and supratentorial GBM (sGBM) patients is eight months, though sGBM had a worse prognosis as the study progressed [30]. Also, patients with brain overlap tumors have a higher tendency to develop GBM than GCG (P<0.001). Because GBM is more common than GCG, it affects brain overlap regions more than supra- and infratentorial regions (which are affected more by GCG, P<0.001). This accounts for the higher mortality rate. Non-Spanish-Hispanic people have a higher mortality rate from GBM (88.6%, P<0.001). In
addition, a study done on Americans with glioblastoma suggested that Latinos tend to have a lower incidence of GBM and present slightly younger than non-Latino Whites [31]. However, white people were found to have the highest incidence of death from GBM and GCG as compared to individuals of other races (P<0.001).

5. Conclusions

GCG was not statistically significant in terms of its association with reduced mortality. Factors such as being female, being age >59, and having a year of diagnosis before 2010 were independently associated with increased mortality. The Spanish-Hispanic ethnicity was independently protective from GBM and GCG as compared to the Non-Spanish-Hispanic ethnicity. Additional studies should be conducted on GBM and GCG patients with the inclusion of important factors such as tumor size and insurance.

Author Contributions: conceptualization, A.K.B and J.G.R.; methodology, A.K.B; formal analysis, A.K.B; Y.R.B; A.M.F; Supervision, K.A.B and J.G.R; X.X; writing—original draft preparation, A.K.B; Y.R.B; A.M.F, J.G.R; K.A.B writing—review and editing, A.K.B and K.A.B

Funding: This research received no external funding.

Acknowledgments

We acknowledge Pura Rodríguez for her support in data analysis.

Conflicts of Interest:

The authors declare no conflict of interest.
References:

1. Surveillance, Epidemiology, and End Results Program. Cancer of the Brain and Other Nervous System - Cancer Stat Facts. Available online: https://seer.cancer.gov/statfacts/html/brain.html Accessed on July 8, 2017.

2. American Brain Tumor Association | Glioblastoma (GBM). Available online: http://www.abta.org/brain-tumor-information/types-of-tumors/glioblastoma.html Accessed on July 8, 2017.

3. Nizamudinov D, Stock EM, Dandashi JA, et al. Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma. World Neurosurg 2018;109:67-74.

4. Stupp R, Mason W, van den Bent M. “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”. Oncology Times. 2005;27(9):15-16.

5. Li R, Li H, Yan W et al. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget. 2015;6(9):7318–7324.

6. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108.

7. Pietschmann S, von Bueren A, Kerber M, Baumert B, Kortmann R, Müller K. An Individual Patient Data Meta-Analysis on Characteristics, Treatments and Outcomes of Glioblastoma/Gliosarcoma Patients with Metastases Outside of the Central Nervous System. PLoS ONE. 2015;10(4):e0121592.

8. Stummer W, Reulen H, Meinel T et al. Extent of Resection and Survival in Glioblastoma Multiforme. Neurosurgery. 2008;62(3):564-576.
9. Ostrom Q, Gittleman H, Farah P et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. Neuro-oncology. 2013;15(suppl 2):ii1-ii56.

10. Beyer S, von Bueren A, Klautke G et al. A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015. PLoS ONE. 2016;11(2):e0148312.

11. Kozak K, Moody J. Giant cell glioblastoma: A glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro-oncology. 2009;11(6):833-841.

12. Surveillance, Epidemiology, and End Results Program. Available online: https://seer.cancer.gov/. Accessed on July 15, 2017.

13. Furnari F, Fenton T, Bachoo R et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21(21):2683-2710.

14. http://www.brainlife.org/abstract/2017/Mesfin_F170715.pdf. Accessed on November 30, 2018. Available online: https://www.ncbi.nlm.nih.gov/books/NBK441874/#_NBK441874_pubdet

15. Johnson D, Leeper H, Uhm J. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis. Cancer. 2013;119(19):3489-3495.

16. Li X, Li Y, Cao Y et al. Risk of Subsequent Cancer among Pediatric, Adult and Elderly Patients Following a Primary diagnosis of glioblastoma multiforme: a Population-based Study of the SEER Database. International Journal of Neuroscience. 2017;127(11):1005-1011.

17. Lin Q, Wagner W. Epigenetic Aging Signatures Are Coherently Modified in Cancer. PLoS Genet. 2015;11(6):e1005334.
18. Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 Wild Type Anaplastic Astrocytomas Exhibit Worse Prognosis than IDH1-mutated Glioblastomas, and IDH1 Mutation Status Accounts for the Unfavorable Prognostic Effect of Higher Age: Implications for Classification of Gliomas. Acta Neuropathol. 2010;120(6):707-718.

19. Murthy V, Krumholz H, Gross C. Participation in Cancer Clinical Trials. JAMA. 2004;291(22):2720.

20. Rong X, Yang W, Garzon-Muvdi T et al. Influence of Insurance Status on Survival of Adults with Glioblastoma Multiforme: A Population-based Study. Cancer. 2016;122(20):3157-3165.

21. Shah B, Bista A, Sharma S. Survival Trends in Elderly Patients with Glioblastoma in the United States: A Population-based Study. Anticancer Res. 2016;36(9):4883-4886.

22. Verger E, Valduvieco I, Caral L et al. Does gender matter in glioblastoma? Clinical and Translational Oncology. 2011;13(10):737-741.

23. Ohgaki H, Dessen P, Jourde B et al. Genetic Pathways to Glioblastoma. Cancer Res. 2004;64(19):6892-6899.

24. Matsuda M, Yamamoto T, Ishikawa E et al. Prognostic Factors in Glioblastoma Multiforme Patients Receiving High-dose Particle Radiotherapy or Conventional Radiotherapy. Br J Radiol. 2011;84(1):S54-S60.

25. Colen R, Wang J, Singh S, Gutman D, Zinn P. Glioblastoma: Imaging Genomic Mapping Reveals Sex-specific Oncogenic Associations of Cell Death. Radiology. 2015;275(1):215-227.
26. Shinojima N, Kochi M, Hamada J et al. The Influence of Sex and the Presence of Giant Cells on Postoperative Long-term Survival in Adult Patients with Supratentorial Glioblastoma Multiforme. J Neurosurg. 2004;101(2):219-226.

27. Loukas M. Adult Brain Cancer in the U.S. Black Population: A Surveillance, Epidemiology, and End Results (SEER) Analysis of Incidence, Survival, and Trends. Medical Science Monitor. 2014;20:1510-1517

28. R Koul, A Dubey, V Torri, A Kakumanu, K Goyal. Glioblastoma Multiforme In Elderly Population. The Internet Journal of Neurosurgery. 2012;8(1):1-7.

29. Pan I, Ferguson S, Lam S. Patient and Treatment Factors Associated with Survival among Adult Glioblastoma Patients: A USA Population-based Study from 2000–2010. Journal of Clinical Neuroscience. 2015;22(10):1575-1581.

30. Jeswani S, Nuño M, Folkerts V, Mukherjee D, Black K, Patil C. Comparison of Survival Between Cerebellar and Supratentorial Glioblastoma Patients. Neurosurgery. 2013;73(2):240-246.

31. Shabihkhani M, Telesca D, Movassaghi M et al. Incidence, Survival, Pathology, and Genetics of Adult Latino Americans with Glioblastoma. J Neurooncol. 2017;132(2):351-358.